Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.65 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.61 |
| ▸ | MME | P08473 | 6/20 | 0.60 |
| ▸ | ACE | P12821 | 4/20 | 0.60 |
| ▸ | CPA1 | P15085 | 2/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244849 | 0.88 | HDAC1 (0.70) | HDAC1HDAC6NPC1LMNARAB9A | |
| SCHEMBL1815011 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL22494096 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL22494095 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL4066786 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL9666114 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL22494097 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL21998924 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL9506671 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL9716823 | 0.87 | FAAH (0.81) | FAAHITGB3ITGA2BHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767718-B2 | CYCLODEPSIPEPTIDE INTERMEDIATES USED TO SYNTHESIZE NEW LIPODEPSIPEPTIDE ; ANTIBIOTICS; HAVE ANTIBACTERIAL ACTIVITY AGAINST GRAM POSITIVE BACTERIA; LESS TOXIC THAN ANTIBIOTIC DAPTOMYCIN | BIOSOURCE PHARM, INC. | 2004-07-27 | — | — | US | disclosed |
| US-20030224475-A1 | Lipodepsipeptide antibiotics and methods of preparation | BIOSOURCE PHARM, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030224475-A1 | Lipodepsipeptide antibiotics and methods of preparation | NPEPPS, MRPL38, LYPLA2 | FAAH 1480/4885ITGB3 4822/4885ITGA2B 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.